New Nanoparticle Formulation for Cyclosporin A: In Vitro Assessment

Gendron, Amandine; Tran, Natalie; Laloy, Julie; Brusini, Romain; Rachet, Aurélie; Gobeaux, Frédéric; Nicolas, Valérie; Chaminade, Pierre; Abreu, Sonia; Desmaële, Didier; Varna, Mariana

doi:10.3390/pharmaceutics13010091

Cited by 7 publications

(3 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were concordant with our previous work done with H9c2, (cardiomyoblast cell line) and MCEC (Mouse Cardiac Endothelial Cells), where accumulation of fluorescent SQ-based NPs was strongly detected after 18 h of incubation [ 25 ]. In a previous work, our group demonstrated that the LDL Receptor was involved in SQAd NPs internalization by HepG2 cells [ 26 ].…”

Section: Resultssupporting

confidence: 93%

Assessment of Squalene-Adenosine Nanoparticles in Two Rodent Models of Cardiac Ischemia-Reperfusion

Brusini,

Tran,

Cailleau

et al. 2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Reperfusion injuries after a period of cardiac ischemia are known to lead to pathological modifications or even death. Among the different therapeutic options proposed, adenosine, a small molecule with platelet anti-aggregate and anti-inflammatory properties, has shown encouraging results in clinical trials. However, its clinical use is severely limited because of its very short half-life in the bloodstream. To overcome this limitation, we have proposed a strategy to encapsulate adenosine in squalene-based nanoparticles (NPs), a biocompatible and biodegradable lipid. Thus, the aim of this study was to assess, whether squalene-based nanoparticles loaded with adenosine (SQAd NPs) were cardioprotective in a preclinical cardiac ischemia/reperfusion model. Obtained SQAd NPs were characterized in depth and further evaluated in vitro. The NPs were formulated with a size of about 90 nm and remained stable up to 14 days at both 4 °C and room temperature. Moreover, these NPs did not show any signs of toxicity, neither on HL-1, H9c2 cardiac cell lines, nor on human PBMC and, further retained their inhibitory platelet aggregation properties. In a mouse model with experimental cardiac ischemia-reperfusion, treatment with SQAd NPs showed a reduction of the area at risk, as well as of the infarct area, although not statistically significant. However, we noted a significant reduction of apoptotic cells on cardiac tissue from animals treated with the NPs. Further studies would be interesting to understand how and through which mechanisms these nanoparticles act on cardiac cells.

show abstract

Section: Resultssupporting

confidence: 93%

Assessment of Squalene-Adenosine Nanoparticles in Two Rodent Models of Cardiac Ischemia-Reperfusion

Brusini,

Tran,

Cailleau

et al. 2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…More recently, new formulations using PLGA-, squalene- or lipid-based nanoparticles were developed to increase cell permeability of the therapeutic CsA but no preclinical study was yet performed ( 126 – 128 ). Also, combined administration of polymeric nanoparticles encapsulating CsA or pitavastatin (organic compound) targeting mPTP opening and monocyte-mediated inflammation, respectively, has been reported to be more efficient than a single administration of encapsulated CsA ( 129 ) even if CsA impacts per se the immune response after myocardial IR ( 130 ).…”

Section: Therapeutic Peptides Reducing Apoptosis To Treat Mirimentioning

confidence: 99%

Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury

Rico

Konate

Josse

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) including acute myocardial infarction (AMI) rank first in worldwide mortality and according to the World Health Organization (WHO), they will stay at this rank until 2030. Prompt revascularization of the occluded artery to reperfuse the myocardium is the only recommended treatment (by angioplasty or thrombolysis) to decrease infarct size (IS). However, despite beneficial effects on ischemic lesions, reperfusion leads to ischemia-reperfusion (IR) injury related mainly to apoptosis. Improvement of revascularization techniques and patient care has decreased myocardial infarction (MI) mortality however heart failure (HF) morbidity is increasing, contributing to the cost-intense worldwide HF epidemic. Currently, there is no treatment for reperfusion injury despite promising results in animal models. There is now an obvious need to develop new cardioprotective strategies to decrease morbidity/mortality of CVD, which is increasing due to the aging of the population and the rising prevalence rates of diabetes and obesity. In this review, we will summarize the different therapeutic peptides developed or used focused on the treatment of myocardial IR injury (MIRI). Therapeutic peptides will be presented depending on their interacting mechanisms (apoptosis, necroptosis, and inflammation) reported as playing an important role in reperfusion injury following myocardial ischemia. The search and development of therapeutic peptides have become very active, with increasing numbers of candidates entering clinical trials. Their optimization and their potential application in the treatment of patients with AMI will be discussed.

show abstract

“…Cyclosporine A (CsA) is an immunosuppressive drug that can inhibit the abnormal immune response of the body and is widely used in clinical practice to prevent and treat transplant rejection, diseases caused by hypersensitivity reactions, and autoimmune diseases, etc. [1][2][3][4][5][6][7][8][9] However, the blood concentration of CsA is closely related to the degree of immunosuppression and hepatic and renal toxicity, showing great intraindividual and interindividual pharmacokinetic differences and a relatively narrow therapeutic window. [10][11][12] Therefore, blood concentration must be monitored promptly during clinical application to ensure the therapeutic effect while minimizing rejection reactions and toxic side effects.…”

Section: Introductionmentioning

confidence: 99%